We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ROP is seeing strong demand for NDI tracking solutions and Verathon's BFlex and GlideScope offerings.
Roper expects total 2026 revenue growth of about 8% and organic growth of roughly 5-6%.
Roper Technologies, Inc. (ROP - Free Report) is witnessing persistent strength in the Technology Enabled Products segment, driven by strong momentum in medical products businesses. Growth in demand for electromagnetic tracking solutions across neurological, cardiac and orthopedic precision measurement applications is fostering the growth of the NDI business within the segment.
Solid performance of the Verathon business, supported by strength across single-use BFlex & GlideScope offerings, bodes well for the segment. The company remains optimistic about new product introductions planned for the rest of the year. Also, the growing popularity of its cloud-based software solution is likely to aid the Neptune business. In first-quarter 2026, the segment’s organic revenues increased 7.1% on a year-over-year basis. For the balance of the year, Roper expects the segment’s organic revenues to increase in the mid-single-digit range.
Also, the growing popularity of its products and solutions across the Deltek, Vertafore, PowerPlan and Aderant businesses is driving ROP’s Application Software segment. Apart from this, strong momentum across the ConstructConnect, Subsplash and SoftWriters businesses, augurs well for its Network Software unit. Driven by strength across its businesses, the company expects total revenues to increase approximately 8% in 2026 from the year-ago level. Organic revenues are estimated to rise approximately 5-6% year over year.
Performance Snapshot of ROP’s Peers
Among its major peers, Agilent Technologies, Inc. (A - Free Report) has a significant exposure to the healthcare industry, which holds long-term prospects. Agilent’s strength in liquid chromatography systems and components and liquid chromatography mass spectrometry systems remains a plus. The broad-based demand in pharma, diagnostics and applied markets remains a tailwind for Agilent.
Rockwell Automation, Inc. (ROK - Free Report) is benefiting from broadening its portfolio of hardware and software products, solutions and services. In Rockwell's Life Science business, the combination of FactoryTalk Pharma Suite MES and FactoryTalk Optix helped secure a competitive win for an active pharma ingredient application. For fiscal 2026, Rockwell raised both its reported and organic sales growth view to 5-9% year over year.
ROP’s Price Performance, Valuation and Estimates
Shares of Roper have gained 5.2% in the past month compared with the industry’s growth of 2.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 14.58X compared with the industry’s average of 17.57X. Roper carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ROP’s 2025 and 2026 earnings has increased over the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Strength in Technology Enabled Products Drives Roper: Can the Momentum Sustain?
Key Takeaways
Roper Technologies, Inc. (ROP - Free Report) is witnessing persistent strength in the Technology Enabled Products segment, driven by strong momentum in medical products businesses. Growth in demand for electromagnetic tracking solutions across neurological, cardiac and orthopedic precision measurement applications is fostering the growth of the NDI business within the segment.
Solid performance of the Verathon business, supported by strength across single-use BFlex & GlideScope offerings, bodes well for the segment. The company remains optimistic about new product introductions planned for the rest of the year. Also, the growing popularity of its cloud-based software solution is likely to aid the Neptune business. In first-quarter 2026, the segment’s organic revenues increased 7.1% on a year-over-year basis. For the balance of the year, Roper expects the segment’s organic revenues to increase in the mid-single-digit range.
Also, the growing popularity of its products and solutions across the Deltek, Vertafore, PowerPlan and Aderant businesses is driving ROP’s Application Software segment. Apart from this, strong momentum across the ConstructConnect, Subsplash and SoftWriters businesses, augurs well for its Network Software unit. Driven by strength across its businesses, the company expects total revenues to increase approximately 8% in 2026 from the year-ago level. Organic revenues are estimated to rise approximately 5-6% year over year.
Performance Snapshot of ROP’s Peers
Among its major peers, Agilent Technologies, Inc. (A - Free Report) has a significant exposure to the healthcare industry, which holds long-term prospects. Agilent’s strength in liquid chromatography systems and components and liquid chromatography mass spectrometry systems remains a plus. The broad-based demand in pharma, diagnostics and applied markets remains a tailwind for Agilent.
Rockwell Automation, Inc. (ROK - Free Report) is benefiting from broadening its portfolio of hardware and software products, solutions and services. In Rockwell's Life Science business, the combination of FactoryTalk Pharma Suite MES and FactoryTalk Optix helped secure a competitive win for an active pharma ingredient application. For fiscal 2026, Rockwell raised both its reported and organic sales growth view to 5-9% year over year.
ROP’s Price Performance, Valuation and Estimates
Shares of Roper have gained 5.2% in the past month compared with the industry’s growth of 2.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 14.58X compared with the industry’s average of 17.57X. Roper carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ROP’s 2025 and 2026 earnings has increased over the past 60 days.
Image Source: Zacks Investment Research
Roper currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.